Jensen MH, et al. - This study draws on data from the Danish National Patient Registry to examine the safety of antihyperglycemic dual and triple therapies for type 2 diabetes (T2D) management with respect to major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality in a real-life clinical setting. In total, of 66,807 people with T2D were treated with metformin (MET) including a combination of second- and third-line therapies. Individuals on MET plus sulfonylurea (SU) had the greatest risk at all endpoints, except for severe hypoglycemia, for which people on MET plus basal insulin (BASAL) were at greater risk. SU as the second-line treatment choice for patients with T2D were not supported in this analysis. Furthermore, the results indicate that adding a GLP-1 could be considered for people treated with MET and BASAL, particularly if those people suffer from severe hypoglycemia.